Our Blog

Welcome to the CERES Regulatory Services blog! Here, you’ll find a wide range of articles and resources on Accelerated Approval Pathways and FDA Fast Track Designation, FDA Breakthrough Therapy Designation, FDA Priority Review Designation, FDA Approval Process, Regulatory Strategy for Therapeutics (Drugs, Biologics, Vaccines, Medical Devices, Cell and Gene Therapy and Advanced Tissue Products), Nonclinical Development, Clinical Development, FDA Meetings, Drug Development Pathways, Expedited Drug Approval, Innovative Therapies Development, NDA and BLA Submission Strategies, FDA Regulatory Guidance, FDA Accelerated and Expedited programs and Strategies of Interest to the Regulatory Scientist.

The Lumakras Resubmission Journey: From FDA CRL to Approval 

Categories: Fractional Regulatory Solutions
70

Hello Regulatory Scientists, 

Today, let’s explore the journey of Lumakras (sotorasib) from receiving an FDA Complete Response Letter (CRL) to achieving approval. This case study provides valuable insights and lessons that can guide companies developing new drugs today. 

Regulatory History and Initial Submission 

Drug: Lumakras (sotorasib) 
Mechanism of Action: KRAS G12C inhibitor, which targets a specific mutation in the KRAS gene, preventing cancer cell proliferation 
Indication: Treatment of KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) 
Initial Submission Date: December 2019 

The Complete Response Letter (CRL) 

CRL Date: July 2020 
CRL Concerns: 

  1. Efficacy Data: The FDA requested additional efficacy data to support the clinical benefit of Lumakras, particularly focusing on response durability. 
  1. Safety Data: Concerns were raised about the safety profile, including potential adverse effects that required further investigation. 
  1. Manufacturing Process: The FDA noted issues related to the quality and consistency of the drug’s manufacturing process. 

Resubmission Strategy 

Amgen, the company behind Lumakras, implemented a comprehensive strategy to address the FDA’s concerns: 

  1. Additional Clinical Trials: Conducted further studies to gather more robust data on the efficacy and safety of Lumakras, focusing on response durability and potential adverse effects. 
  1. Enhanced Safety Monitoring: Provided additional data and analyses on the safety profile, including long-term safety data and management strategies for potential adverse effects. 
  1. Manufacturing Process Improvements: Made significant enhancements to the manufacturing process to ensure consistency and quality. 
  1. Continuous FDA Engagement: Maintained open lines of communication with the FDA to ensure alignment on the resubmission strategy and clarify any outstanding questions. 

Resubmission Date: December 2020 

Outcome 

Approval Date: May 2021 
Lumakras was approved for the treatment of KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer, providing a new therapeutic option for this challenging condition. 

Lessons Learned 

The journey of Lumakras from CRL to approval highlights several key lessons for drug developers: 

  1. Comprehensive Data Collection: Providing extensive clinical data, particularly focusing on response durability and long-term safety, is crucial to addressing FDA concerns. 
  1. Enhanced Safety Monitoring: Ensuring thorough understanding and management of the drug’s safety profile can help mitigate regulatory concerns. 
  1. Manufacturing Process Improvements: Ensuring the quality and consistency of the manufacturing process is vital for regulatory approval. 
  1. Continuous FDA Engagement: Maintaining open and ongoing communication with the FDA helps align development efforts with regulatory expectations. 
  1. Proactive Quality Control: Implementing stringent quality control measures ensures the consistency and reliability of the drug’s production. 

Relevance for Current Drug Developers 

For companies developing drugs today, the Lumakras case underscores the importance of strategic planning and meticulous attention to detail in the regulatory process. Here are some takeaways to help avoid a CRL and achieve first-cycle approval: 

  1. Thorough Pre-Submission Preparation: Ensure that all aspects of your submission, including clinical data, safety data, and manufacturing processes, meet FDA standards. 
  1. Proactive Risk Management: Identify and address potential risks early in the development process to prevent issues from arising during FDA review. 
  1. Engage with the FDA Early and Often: Regular interactions with the FDA can provide valuable guidance and help steer the development process. 
  1. Invest in Quality Data: Prioritize the collection of high-quality, detailed safety and efficacy data to support the submission. 
  1. Utilize Advisory Committees: Seek feedback from advisory committees to validate data and address potential concerns, even if formal hearings are not required. 

By learning from the Lumakras resubmission experience, current drug developers can better navigate the regulatory landscape, avoid common pitfalls, and increase the likelihood of a successful first review cycle approval. 

Stay diligent and strategic, 

CERES Regulatory Services 

Picture of Asad Khan
Asad Khan